KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors. [electronic resource]
Producer: 20120917Description: e38033 p. digitalISSN:- 1932-6203
- Adult
- Aged
- Antineoplastic Agents -- pharmacology
- Class I Phosphatidylinositol 3-Kinases
- Colorectal Neoplasms -- drug therapy
- Female
- Humans
- MAP Kinase Signaling System -- drug effects
- Male
- Middle Aged
- Mutation
- Mutation Rate
- Neoplasm Metastasis
- Phosphatidylinositol 3-Kinases -- genetics
- Protein Kinase Inhibitors -- pharmacology
- Proto-Oncogene Proteins -- genetics
- Proto-Oncogene Proteins c-akt -- metabolism
- Proto-Oncogene Proteins p21(ras)
- Signal Transduction -- drug effects
- TOR Serine-Threonine Kinases -- metabolism
- Treatment Outcome
- ras Proteins -- genetics
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural
There are no comments on this title.
Log in to your account to post a comment.